Betts Keith A, Woolley J Michael, Mu Fan, McDonald Evangeline, Tang Wenxi, Wu Eric Q
a Analysis Group Inc. , Boston , MA , USA.
b ZS Pharma, a member of the AstraZeneca Group , San Mateo , CA , USA.
Curr Med Res Opin. 2018 Jun;34(6):971-978. doi: 10.1080/03007995.2018.1433141. Epub 2018 Feb 21.
The retrospective study aimed to estimate prevalence of hyperkalemia using a large US commercial claims database.
Adults with serum potassium lab data (2010 to 2014) and ≥1 calendar year of data were included from a large US commercial claims database. Hyperkalemia was defined as ≥2 serum potassium measurements >5.0 mEq/L or one hyperkalemia diagnosis code (ICD-9-CM, 276.7) or one sodium polystyrene sulfonate fill. Hyperkalemia prevalence was estimated for the overall population and subgroups with hyperkalemia-related comorbidities by calendar year. Hyperkalemia prevalence was also standardized to the US population to estimate the number of US adults with hyperkalemia.
The analysis included 2,270,635 patients (2010-2014). The annual prevalence of hyperkalemia in the overall population was 1.57% in 2014, with higher rates observed in patients with chronic kidney disease (CKD), heart failure, diabetes and hypertension. Among patients with CKD and/or heart failure, the 2014 annual prevalence was 6.35%. Among patients with hyperkalemia, 48.43% had CKD and/or heart failure in 2014. The prevalence of hyperkalemia was higher in patients with more severe CKD, as well as older patients and men. Extrapolating those results to the US population supports that 1.55% or 3.7 million US adults had hyperkalemia in 2014.
An estimated 3.7 million US adults had hyperkalemia in 2014, and this prevalence rate has increased since 2010. In patients with CKD and/or heart failure, the annual prevalence of hyperkalemia was 6.35% in 2014, and about half of all patients with hyperkalemia have either CKD and/or heart failure.
这项回顾性研究旨在利用一个大型美国商业索赔数据库评估高钾血症的患病率。
从一个大型美国商业索赔数据库中纳入了有血清钾实验室数据（2010年至2014年）且有≥1个日历年数据的成年人。高钾血症的定义为≥2次血清钾测量值>5.0 mEq/L或一个高钾血症诊断代码（ICD-9-CM，276.7）或一次聚苯乙烯磺酸钠填充。按日历年估计总体人群及患有高钾血症相关合并症亚组的高钾血症患病率。高钾血症患病率也根据美国人群进行标准化，以估计美国患有高钾血症的成年人数量。
分析纳入了2270635例患者（2010 - 2014年）。2014年总体人群中高钾血症的年患病率为1.57%，在慢性肾脏病（CKD）、心力衰竭、糖尿病和高血压患者中观察到更高的患病率。在患有CKD和/或心力衰竭的患者中，2014年年患病率为6.35%。2014年，在患有高钾血症的患者中，48.43%患有CKD和/或心力衰竭。CKD更严重的患者、老年患者和男性中高钾血症的患病率更高。将这些结果外推至美国人群表明，2014年有1.55%或370万美国成年人患有高钾血症。
2014年估计有370万美国成年人患有高钾血症，且自2010年以来该患病率有所上升。2014年，在患有CKD和/或心力衰竭的患者中，高钾血症的年患病率为6.35%，所有高钾血症患者中约一半患有CKD和/或心力衰竭。
